Canada· CA-DIN-02467542
VOSEVI
A sofosbuvir, velpatasvir and voxilaprevir product containing voxilaprevir + velpatasvir + sofosbuvir, registered in Canada by GILEAD SCIENCES CANADA INC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- VOXILAPREVIR + VELPATASVIR + SOFOSBUVIR
- Manufacturer
- GILEAD SCIENCES CANADA INC
- Country
- Canada (CA)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsVosevi 200 mg/50 mg/50 mg, filmomhulde tablettenGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- PolandVoseviGilead Sciences Ireland UC
- SwedenVosevi 200 mg/50 mg/50 mg Filmdragerad tablettGilead Sciences Ireland UC
- CzechiaVOSEVIGilead Sciences Ireland UC, Carrigtohill
- IrelandVosevi 200 mg/50 mg/50 mg film-coated tabletsGilead Sciences Ireland UC
- IcelandVoseviGilead Sciences Ireland UC*
- United StatesVoseviGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vosevi
- Liechtenstein · Vosevi
- Norway · Vosevi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbb35227-519b-4225-b0df-c59ce130dfc9 GET /v1/drugs/dbb35227-519b-4225-b0df-c59ce130dfc9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02467542",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "J05AP56",
"schedule": [
"Prescription"
],
"drug_code": "95590",
"strengths": [
"100 MG",
"400 MG"
],
"ahfs_class": null,
"substances": [
"VOXILAPREVIR",
"VELPATASVIR",
"SOFOSBUVIR"
],
"product_categorization": null
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.